StreetInsider.com News Articles

Form 4 Veraxa Biotech AG For: Sep 10 Filed by: Hosseinion Warren

Tue, 29 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260929/27122583.html

Form 3 Veraxa Biotech AG - Post For: Sep 01 Filed by: Willener Raju Sudir

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091838.html

Form 3 Veraxa Biotech AG - Post For: Sep 01 Filed by: Willener Raju Sudir

Mon, 14 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260914/27058489.html

Veraxa Biotech names Raju Willener as CFO

Fri, 04 Sep 2026 07:00:27 -0400

VERAXA Biotech AG (NASDAQ: VRXA) has appointed Raju Willener as Chief Financial Officer, effective immediately, according to a company press release. He replaces Carl von Halem in the role and will report to CEO and Co-Founder Christoph Antz, Ph.D.

Willener brings more than three decades of experience in investment banking, corporate finance, asset management and capital markets, with senior roles held across the U.S., Europe and Asia. He previously oversaw investment portfolios exceeding CHF 30 billion in assets under management at global financial institutions.

Most recently, Willener served as Director of Corporate Development at Exentis Group AG before being appointed CFO of

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

Fri, 04 Sep 2026 07:00:00 -0400

Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s pipeline of potential best-in-class therapies led by its BiTAC® platform

Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today announced the appointment of Raju Willener as Chief Financial Officer (CFO), effective immediately. Mr. Willener will report to Christoph Antz, Ph.D., Chief Executive Officer and Co-Founder. Mr. Willener brings more than three decades of financial leadership across global capital markets and

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

Fri, 04 Sep 2026 07:00:00 -0400

Form 6-K Veraxa Biotech AG - Post For: Aug 24

Mon, 24 Aug 2026 07:39:00 -0400

si-local-file:///var/storage/secattach/20260824/26964280.html

Form 6-K Veraxa Biotech AG - Post For: Aug 24

Mon, 24 Aug 2026 07:39:00 -0400

si-local-file:///var/storage/secattach/20260824/26964280.html

Veraxa Biotech and Secarna report early AOC research milestone

Mon, 24 Aug 2026 07:01:46 -0400

Veraxa Biotech AG (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG announced initial positive results from their joint research collaboration to develop antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases, according to a press release.

In early in vitro studies, an AOC candidate produced by combining both companies' technologies showed greater potency compared to an equivalent unconjugated oligonucleotide. The companies said they are now discussing next steps in the alliance, which was established less than a year ago.

Christoph Erkel, Ph.D., Chief Scientific Officer of Veraxa, said the milestone "demonstrates that our conjugation technology powered by

Veraxa Biotech and Secarna report early AOC research milestone

Mon, 24 Aug 2026 07:01:46 -0400

Christoph Erkel, Ph.D., Chief Scientific Officer of Veraxa, said the milestone "demonstrates that our conjugation technology powered by

VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance

Mon, 24 Aug 2026 07:00:00 -0400

Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise

ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, and Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.

VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance

Mon, 24 Aug 2026 07:00:00 -0400

Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise

Form 3 Veraxa Biotech AG - Post For: Jul 10 Filed by: von Halem Carl

Thu, 20 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26956034.html

Form 3 Veraxa Biotech AG - Post For: Jul 10 Filed by: von Halem Carl

Thu, 20 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26956034.html

Veraxa Biotech AG (VRXA) files for 25M share offering by selling stockholders

Fri, 31 Jul 2026 17:16:13 -0400

Veraxa Biotech AG (NASDAQ: VRXA) filed for up to 25,000,000 share offering by selling stockholders.

Veraxa Biotech AG (VRXA) files for 25M share offering by selling stockholders

Fri, 31 Jul 2026 17:16:13 -0400

Veraxa Biotech AG (NASDAQ: VRXA) filed for up to 25,000,000 share offering by selling stockholders.

VERAXA Biotech files first BiTAC patent applications, portfolio tops 50

Wed, 29 Jul 2026 07:03:52 -0400

VERAXA Biotech AG (NASDAQ: VRXA) filed its first patent applications covering its BiTAC technology platforms in the first half of 2026, according to a statement from the Zurich-based company.

The applications cover composition of matter and proprietary payload platforms related to its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) programs. Additional patents were secured in click chemistry and conjugation technology areas.

The company said its total portfolio now includes more than 50 granted owned or exclusively licensed patents across 14 countries, spanning 26 patent families. Previously granted patents covering auxiliary technology modules have also cleared their opposition period.

If the recently filed applications

VERAXA Biotech files first BiTAC patent applications, portfolio tops 50

Wed, 29 Jul 2026 07:03:52 -0400

VERAXA Biotech AG (NASDAQ: VRXA) filed its first patent applications covering its BiTAC technology platforms in the first half of 2026, according to a statement from the Zurich-based company.

If the recently filed applications

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

Wed, 29 Jul 2026 07:00:00 -0400

First BiTAC®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology areas including click chemistry and conjugation technology.

ZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided an update on its core patent portfolio. During the first half of 2026, first patent applications were filed to cover the Company’s new generation of technologies including its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) platforms

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

Wed, 29 Jul 2026 07:00:00 -0400

VERAXA Biotech advances VXA-222 bispecific ADC program with OmniAb

Mon, 27 Jul 2026 07:00:46 -0400

VERAXA Biotech AG (NASDAQ: VRXA) announced the advancement of its bispecific antibody drug conjugate program VXA-222 following the achievement of a key technical milestone in its collaboration with OmniAb, Inc. (NASDAQ: OABI).

The program moves into its next phase with OmniAb's discovery work concluded. VXA-222 uses an "AND-gate" mechanism designed to address two different target antigens present on solid tumors within a single molecule.

The collaboration, established in May 2025, combined OmniAb's transgenic antibody discovery solutions and screening technologies with VERAXA's proprietary ADC linker technology and conjugation expertise. OmniAb's OmniClic platform, a common light-chain transgenic chicken system, was used to generate bispecific

VERAXA Biotech advances VXA-222 bispecific ADC program with OmniAb

Mon, 27 Jul 2026 07:00:46 -0400

VERAXA Biotech advances VXA-222 bispecific ADC program with OmniAb

Mon, 27 Jul 2026 07:00:46 -0400

VERAXA Biotech advances VXA-222 bispecific ADC program with OmniAb

Mon, 27 Jul 2026 07:00:46 -0400

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

Mon, 27 Jul 2026 07:00:00 -0400

VXA-222 advances into next phase at VERAXA

ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb, Inc. (NASDAQ: OABI, “OmniAb”). The program is moving into its next collaboration phase with OmniAb's discovery work successfully concluded. VXA-222 utilizes an “AND-gate” logic to address two different target antigens present on solid tumors with one molecule. Established in May 2025, the